GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Vivus, Inc. (VVUS) [hlAlert]

Rating:
Underperform
VVUS
up 1,774.77 %

Vivus, Inc. (VVUS) downgraded to Underperform by Jefferies

Posted on: Friday,  Aug 17, 2012  8:25 AM ET by Jefferies

Jefferies rated Underperform Vivus, Inc. (NASDAQ: VVUS) on 08/17/2012, when the stock price was $20.81. Since
then, Vivus, Inc. has lost 94.67% as of 01/25/2016's recent price of $1.11.
If you would have followed this Jefferies's recommendation on VVUS, you would have gained 1774.77% of your investment in 1256 days.

Vivus, Inc. is a leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders in men and women. They develop and market the product MUSE and the medical device ACTIS, two innovations in the treatment of erectile dysfunction. The company has partnered with Abbott Laboratories for the international marketing and distribution of its male erectile dysfunction products. VIVUS also has research and development programs in premature ejaculation and erectile dysfunction. (Company Press Release)

Jefferiess' research efforts cover U.S. & International equity, high yield, convertibles, derivatives and option strategies, investment grade fixed income, post-reorganization securities, as well as special situations and quantitative research. Our team of more than 150 research professionals covers nearly 1,200 companies in more than 40 industries worldwide. Our analysts focus on identifying emerging industry themes while providing in-depth, thought provoking, objective research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/17/2012 8:25 AM Sell
None
20.81
as of 12/31/2012
1 Week down  -0.14 %
1 Month down  -18.76 %
3 Months up  24.64 %
1 YTD down  -166.13 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/18/2012 8:25 AM Hold
None
29.41
7/16/2010 8:25 AM Sell
None
5.12 3.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy